Sign inJoin waitlistJoin the waitlist

Deepa Jagadeesh

Clinical Assistant Professor, Department of Medicine, School of Medicine · Case Western Reserve University

Credentials: · · · · ·

History

Case Western Reserve University
Present

Hematology and Medical Oncology
UMass Chan Medical School
2009–2012
Internal Medicine
UMass Chan Medical School
2005–2008
Boston University
University of Mysore, JJM Medical College
1992–1996

Research

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2023 · 204 citations
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC…
The Lancet Haematology · 2018 · 186 citations
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2022 · 169 citations

Robert Dean
48 papers
Brian Hill
47 papers
BP
Brad Pohlman
43 papers
Matt Kalaycio
34 papers
Ronald Sobecks
33 papers
NM
Navneet Majhail
32 papers
Betty Hamilton
29 papers
Aaron Gerds
24 papers
BB
Brian Bolwell
21 papers
HL
Hien Liu
17 papers
MS
Mitchell Smith
16 papers
Paolo Caimi
16 papers

Grants

Case Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $167.4K · Case Western Reserve University

Clinical trials

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
Principal investigator · Terminated · Phase 1, Phase 2
Deepa Jagadeesh
2021–2023
Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder
Principal investigator · Terminated · Phase 2
Deepa Jagadeesh
2020–2022
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Principal investigator · Completed · Phase 2
Deepa Jagadeesh
2016–2024
MB-105 in Patients With CD5 Positive T-cell Lymphoma
Site PI · Recruiting · Phase 2
March Biosciences Inc
2025–2029